Non-squamous non-small cell lung cancer
Conditions
Interventions
CBDCA+PEM+Bevacizumab
Sponsors
Kurume University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) In histological or cytological diagnosis, diagnosis of the non-squamous and non-small cell lung cancer is obtained 2) More than 75 years old at the time of the agreement acquisition 3) Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 0-1 4) With the measurable disease based on Response Evaluation Criteria in solid Tumors (RECIST) v. 1.1 5) There is not systemic chemotherapy history for non-squamous cell and small cell carcinoma, expect UFT for adjuvant therapy or therapy for pleurodesis and first line of EGFR-TKI or Crizotinib 6) With adequate organ function within one week before study entry 7) The expected survival more than 90 days from the enrollment 8) An agreement by the document from a patient
Exclusion criteria
Exclusion criteria: 1) The case that there is previous treatment history 2) With the active double primary cancer 3) With the pleural effusion or pericardial effusion to need drainage 4) With the metastatic brain tumor to need treatment, such as radiotherapy or steroid 5) History of active hemoptysis with 2,5 ml or more 6) The case that a hemorrhage risk is high a) With the necessity of the administration of anticoagulant and antiplatelet agent b) With the the tumor invasion to great vessels c) With the cavity lesion 7) With the following complication or past history a) With the merger or history of cerebrovascular disease to need treatment b) With the history of perforation gastrointestinal, fistula, diverticulitis c) With the diarrhea, paresis of intestine, ileus d) With the merger or history of angina or myocardial infarction, cardiac failure to need treatment e) With the uncontrol diabetes f) With the interstitial pneumonia g) With the uncontrol infectious disease h) With the history of serious drug allergy i) With the uncontrol hypertension even if taking the hypotensive drug 8) With the mental disease 9) The patient whom attending physician judged to be inadequate to perform the study treatment safely
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Countries
Japan
Contacts
Public ContactKazuhiko Yamada
Department of Internal Medicine, Kurume University School of Medicine Division of Respirology, Neurology, and Rheumatology
Outcome results
None listed